Merck

Tweet this page
<
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
>
Registration as it was on 25 Oct 2023
How to read and use this data card.
Download this datacard
The following entries are flagged as duplicates of this organisation: 55120759781-59

Overview

Lobbying Costs

1,000,000€ - 1,249,999€

Financial year: Jan 2022 - Dec 2022

Lobbyists (Full time equivalent)

2.35 Fte (6)

Lobbyists with EP accreditation

6

High-level Commission meetings

16

Lobbying Costs over the years

  • Info

    Merck

    EU Transparency Register

    49654992078-52 First registered on 28 Jul 2009

    Goals / Remit

    Merck, a leading science and technology company, generated total revenues of €22,2 billion in 2022 with its divisions Healthcare, Electronics and Life Science. More than 64,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent stakes, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are the United States and Canada. Here Merck operates as EMD Serono in the Biopharma business, MilliporeSigma in the Life Science business, and as EMD Performance Materials in the Performance Materials/Electronics business.

    Main EU files targeted

    European Green Deal and all relevant policies/initiatives such as:
    Chemicals Strategy for Sustainability - REACH revision, Industrial Emissions Directive, Clean Air and Water, Fit-for-55 packages, CLP regulation, Circular Economy policies? PFAS

    Industrial Policy Strategy, EU Economic Security Strategy
    Raw-Materials Act
    Digital Policies (i.e. EU Chips-Act, EU AI Act, EHDS)
    Trade policies (eg Global Gateway, customs regulations, TTC developments)
    Sustainable Finance (eg Taxonomy)

    Pharmaceutical Strategy and Health Care related policies.
    Intellectual Property (IP) Package

    Life Science related policies such as Medicinal Products Directive.

    Sanctions Packages on Russia etc.

    Address

    Head Office
    Frankfurter Strasse 250
    Darmstadt 64293
    GERMANY
    EU Office
    Rue Belliard 40
    Brüssel 1040
    BELGIUM

    Website

  • People

    Total lobbyists declared

    6

    Employment timeLobbyists
    50%4
    25%1
    10%1

    Lobbyists (Full time equivalent)

    2.35

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    6 accreditations were / are live (in bold) for the selected state of 24 Jul 2024

    Name Start date End Date
    Liesbet DENDAS 25 Jun 2024 24 Jun 2025
    Elisa DIAZ MARTINEZ 06 Dec 2023 05 Dec 2024
    Sabrina CONTI 24 Jan 2024 23 Jan 2025
    Maike BECKER-KRÜGER 10 May 2023 10 May 2024
    Ana POLANCO ALVAREZ 24 Jan 2024 23 Jan 2025
    Jean Paul Andre EL AHL 14 Sep 2023 13 Sep 2024
    Franjo CAIC 14 Oct 2023 11 Oct 2024
    Ana POLANCO ALVAREZ 01 Mar 2023 24 Jan 2024
    Sabrina CONTI 19 Jan 2023 18 Jan 2024
    Mr Tim MERTENS 14 Dec 2022 10 May 2023
    Franjo CAIC 29 Oct 2022 14 Oct 2023
    Ms Liesbet DENDAS 06 Jul 2022 06 Jul 2023
    Jean Paul Andre EL AHL 06 Jul 2022 06 Jul 2023
    Mr Tim MERTENS 09 Oct 2021 08 Oct 2022
    Franjo CAIC 08 Oct 2021 08 Oct 2022
    Jean Paul Andre EL AHL 25 Aug 2021 06 Jul 2022
    Ms Anne PAPIN DI POMPEO 27 Jul 2021 27 Jul 2022
    Mr Hugh Thomas PULLEN 20 Feb 2020 20 Feb 2021
    Ms Anne PAPIN DI POMPEO 20 Feb 2020 20 Feb 2021
    Ms Mihaela Militaru 20 Feb 2020 20 Feb 2021
    Ms Irene Maria DE CARA 20 Feb 2020 20 Feb 2021
    Ms Vanessa POTT 20 Feb 2020 20 Feb 2021
    Mr Tim MERTENS 19 Nov 2019 01 Dec 2020
    Ms Isabel VLACHOPOULOU KLINNERT 27 Mar 2019 27 Mar 2020
    Ms Anne PAPIN DI POMPEO 16 Jan 2019 16 Jan 2020
    Ms Mihaela Militaru 16 Jan 2019 16 Jan 2020
    Mr Hugh Thomas PULLEN 08 Jan 2019 01 Jan 2020
    Ms Irene Maria DE CARA 08 Jan 2019 01 Jan 2020
    Ms Vanessa POTT 04 Oct 2018 01 Nov 2019
    Franjo CAIC 28 Mar 2018 28 Mar 2019
    Ms Isabel VLACHOPOULOU KLINNERT 15 Mar 2018 15 Mar 2019
    Mr Hugh Thomas PULLEN 25 Nov 2017 24 Nov 2018
    Ms Mihaela Militaru 25 Nov 2017 24 Nov 2018
    Ms Irene Maria DE CARA 25 Nov 2017 24 Nov 2018
    Ms Anne PAPIN DI POMPEO 31 Aug 2017 31 Aug 2018
    Ms Vanessa POTT 20 Jul 2017 20 Jul 2018
    Ms Sara-Andrada Dumitrana 22 Mar 2017 21 Mar 2018
    Franjo CAIC 22 Mar 2017 21 Mar 2018
    Mr Hugh Thomas PULLEN 09 Nov 2016 09 Nov 2017
    Ms Irene Maria DE CARA 04 Nov 2016 03 Nov 2017
    Ms Mihaela Militaru 28 Oct 2016 28 Oct 2017
    Mr Marcel Daniels 19 Jul 2016 08 Jul 2017
    Ms Sara-Andrada Dumitrana 16 Feb 2016 04 Feb 2017
    Mr Marcel Daniels 17 Jun 2015 15 Jun 2016
    Mr Hugh Thomas PULLEN 17 Jun 2015 15 Jun 2016
    Ms Sara-Andrada Dumitrana 04 Nov 2014 30 Oct 2015
    Mrs Sara-Andrada Dumitrana 04 Nov 2014 27 Jan 2015
    Mr Hugh Thomas PULLEN 07 Jun 2014 05 Jun 2015
    Mr Marcel Daniels 06 May 2014 15 Apr 2015

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Companies & groups

  • Networking

    Affiliation

    Merck is a member of CEFIC (EU), EFPIA (EU), EBE - European Biopharmaceutical Enterprises (EU), EuropaBio, BVAC (DE with EU-office), VCI (DE) and its sub-state organisations such as LV Hessen, and DIB (Deutsche Industrievereinigung Biotechnologie), Bundesverband der deutschen Industrie (BDI), Verband forschender Arzneimittelhersteller (DE), World Economic Forum (WEF), Bitkom (DE), European Round Table of Industrialists (ERT), Cosmetics Europe, EUCCC (European Chamber of Commerce), ACATECH and various other sectoral organisations mainly at respective national/regional levels in the countries such as European General Counsel Association (UK), European Process Safety Center (UK), European Centre for Ecotoxicology and Toxicology of Chemicals (BE)

    Member organisations

    see above

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2022 - Dec 2022

    Lobbying costs for closed financial year

    1,000,000€ - 1,249,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    NameAmount
    harwood levitt consulting 100,000€ - 199,999€
    covington & burling 10,000€ - 24,999€
    nove 25,000€ - 49,999€

    Intermediaries for current year

    Name
    harwood levitt consulting
    nove

    Closed year Costs

    1,000,000€ - 1,249,999€

    Other financial info

    Any possible research/innovation fundings received and vice versa made available by Merck (e.g. in kind contributions) are not recorded.
    Costs increased in 2022 due to the high number of important files that required more work with EU Institutions (General Pharmaceutical Legislation, Green Deal, PFAS,...)

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    N/A

    Communication activities

    2022: Sponsoring of a Health Talk in Brussels on the topic of the General Pharmaceutical Strategy, with representatives of the EU Commission, EU Parliament, and several stakeholders.

    Other activities

    None declared

  • Meetings

    Meetings

    16 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

    1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.

    • Date 05 Jun 2023 Location Brussels
      Subject Trade & Technology Council, Global Steel and Aluminum Arrangement, Critical Minerals Agreement
      Cabinet Cabinet of Executive Vice-President Valdis Dombrovskis
      Portfolio An Economy that Works for People
      Attending
      • Elina Melngaile (Cabinet member)
      • Zaneta Vegnere (Cabinet member)
      Other Lobbyists
    • Date 18 Feb 2023 Location München
      Subject Review of pharmaceutical legislation. TRIPS waiver.
      Cabinet Cabinet of Executive Vice-President Valdis Dombrovskis
      Portfolio An Economy that Works for People
      Attending
      • Valdis Dombrovskis (Executive Vice-President)
    • Date 18 Jan 2023 Location Davos, Switzerland
      Subject Deep tech innovation for life sciences & biological components EU Innovation Agenda EU Mission on cancer R&I for health EU Research on semi-conductors
      Cabinet Cabinet of Commissioner Mariya Gabriel
      Portfolio Digital Economy and Society
      Attending
      • Mariya Gabriel (Commissioner)
    • Date 18 Jan 2023 Location Davos, Switzerland
      Subject Deep tech innovation for life sciences & biological components EU Innovation Agenda EU Mission on cancer R&I for health EU Research on semi-conductors
      Cabinet Cabinet of Commissioner Mariya Gabriel
      Portfolio Innovation and Youth
      Attending
      • Mariya Gabriel (Commissioner)
    • Date 08 Nov 2022 Location Brussels
      Subject Share initiatives and explore ways of collaboration and synergy
      Cabinet Cabinet of Commissioner Helena Dalli
      Portfolio Equality
      Attending
      • Lesia Radelicki (Cabinet member)
    • Date 07 Sep 2022 Location Webex
      Subject Revision of the pharmaceutical legislation.
      Cabinet Cabinet of Commissioner Stella Kyriakides
      Portfolio Health
      Attending
      • Karolina Herbout-Borczak (Cabinet member)
    • Date 04 Apr 2022 Location virtual
      Subject Current issues such as the transformation of the European economy, and how the Chemical and Pharmaceutical industry
      Cabinet Cabinet of Commissioner Paolo Gentiloni
      Portfolio Economy
      Attending
      • Alienor Margerit (Cabinet member)
    • Date 30 Nov 2021 Location Brussels
      Subject Pharma Strategy
      Cabinet Cabinet of Vice-President Margaritis Schinas
      Portfolio Promoting the European Way of Life
      Attending
      • Maria Luisa Llano Cardenal (Cabinet member)
      • Margaritis Schinas (Vice-President)
    • Date 26 Oct 2021 Location Brussels
      Subject Pharmaceutical sector – trade related issues
      Cabinet Cabinet of Executive Vice-President Valdis Dombrovskis
      Portfolio An Economy that Works for People
      Attending
      • Elina Melngaile (Cabinet member)
      • Kevin Keary (Cabinet member)
      • Caroline Boeshertz (Cabinet member)
      Other Lobbyists
    • Date 03 Sep 2021 Location Brussels
      Subject FF55 and the pharmaceutical industry
      DG Climate Action
      Attending
      • Mauro Raffaele Petriccione (Director-General)
    • Date 12 Apr 2021 Location Brussels
      Subject Global supply chains for disposables
      Cabinet Cabinet of Commissioner Thierry Breton
      Portfolio Internal Market
      Attending
      • Maurits-Jan Prinz (Cabinet member)
    • Date 02 Mar 2021 Location videoconference
      Subject Vaccine production
      Cabinet Cabinet of Commissioner Thierry Breton
      Portfolio Internal Market
      Attending
      • Thierry Breton (Commissioner)
      Other Lobbyists
    • Date 29 May 2018 Location Brussels
      Subject Preparation of the IMI 10th Anniversary
      Cabinet Cabinet of Commissioner Carlos Moedas
      Portfolio Research, Science and Innovation
      Attending
      • Giulia Del Brenna (Cabinet member)
    • Date 14 Nov 2017 Location Strasbourg
      Subject Circular economy, priorities of Juncker Commission and AMR (Antimicrobial Resistance) Action Plan
      DG Communication
      Attending
      • Timo Pesonen (Director-General)
    • Date 23 Nov 2016 Location Brussels
      Subject EPFIA's Priorities
      Cabinet Cabinet of Commissioner Carlos Moedas
      Portfolio Research, Science and Innovation
      Attending
      • Giulia Del Brenna (Cabinet member)
    • Date 22 Apr 2016 Location Brussels
      Subject HTA
      Cabinet Cabinet of Commissioner Vytenis Andriukaitis
      Portfolio Health &amp; Food Safety
      Attending
      • Annika Nowak (Cabinet member)
Download this datacard